USPTO serial 79164550
ARVEN
Reviewed by CopyMark Law Group
Reg. 5061369Status 404
- Filing date
- Status date
- Registration date
- Oct 18, 2016
- Examiner
- YAO, GRETTA
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ARVEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
ARVEN ILAÇ SANAYI VE TICARET ANONIM SIRKETI
Istinye-Sari, TR
Other trademarks owned by ARVEN ILAÇ SANAYI VE TICARET ANONIM SIRKETI
ARVEN ILAÇ SANAYI VE TICARET ANONIM SIRKETI
TR-34460 ISTANBUL, TR
Other trademarks owned by ARVEN ILAÇ SANAYI VE TICARET ANONIM SIRKETI
ARVEN ILAÇ SANAYI VE TICARET ANONIM SIRKETI
TR-34460 ISTANBUL, TR
Other trademarks owned by ARVEN ILAÇ SANAYI VE TICARET ANONIM SIRKETI
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Aylin Demirci
Aylin Demirci Carr & Ferrell LLP120 Constitution DriveMenlo Park, CA 94025UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals and pharmaceutical preparations for the prevention and treatment of cardiovascular disorders, skeleto-muscular disorders, general infections, viral infections, central nervous system disorders, gastro-intestinal disorders, fungal diseases, allergy, ophthalmic diseases, hemophilia, metabolic diseases, cancer, multiple sclerosis, neutropenia, non-Hodgkin lymphoma, Crohn's Disease, autoimmune disorders, urologic diseases, sexual dysfunction, osteoporosis, and climacteric diseases; pharmaceutical preparations, namely, anticoagulants and platelet aggregation inhibitors, contraceptive preparations, analgesics, anti-pyretics, anti-inflammatory preparations, anti-septic preparations, medicated lip balm, anesthetic spray for topical use, astringents, pediculicides, decongestants, antifungal agents, anti-infective pharmaceutical preparations, antacids, cold preparations in the nature of preparations for treating colds, menstrual symptom treatment preparations and dermatologicals; Pharmaceuticals and pharmaceutical preparations, namely, dry powder inhalers filled with pharmaceutical preparations for the treatment of asthma and respiratory diseases; Inhalation products, namely, inhalers filled with pharmaceutical preparations for the treatment of asthma, respiratory diseases; pharmaceutical preparations used in medical diagnostic procedures, namely, contrast media for use with x-ray, magnetic resonance and ultrasound equipment; veterinary preparations for medical use, namely, anesthetics, combination sedative, analgesic; veterinary preparations for medical use for the treatment of bacterial infections; pharmaceutical preparations, namely, Systemic anti-infectives, namely, antibacterial and antifungal pharmaceuticals; mineral preparations, namely, vitamin and mineral supplements, vitamin and mineral preparations for medical use, vitamin preparations and mineral supplements; Musculo-skeletal system pharmaceutical products for the treatment of musculo-skeletal system diseases; Cardiovascular pharmaceuticals, namely, diuretics, lipid lowering agents, beta blocking agents, calcium antagonists and cardiovascular treatment preparations and cardiovascular agents for medical purposes; Pharmaceuticals for the prevention and treatment of disorders of the nervous system, namely, analgesics, psychoanaleptics, psycoleptics, anti-epileptics, central nervous system drugs, anaesthetics, antiparkinson preparations; Pharmaceuticals for the treatment of respiratory diseases and asthma; Dermatological pharmaceutical products; Pharmaceuticals for the treatment of hormonal disorders and the prevention of osteoporosis; Anti-diabetic pharmaceuticals; Pharmaceuticals for the treatment of bone diseases and joint diseases; Pharmaceuticals for the treatment of viral and infectious diseases; Pharmaceuticals for use as antineoplastic agents; Pharmaceuticals for the treatment of immune system related diseases and disorders; Pharmaceuticals for the treatment of kidney diseases; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals for ophthalmological use; pharmaceutical preparations for the treatment of cardiovascular disorders, skeleto-muscular disorders, general infections, viral infections, central nervous system disorders, gastro-intestinal disorders, fungal diseases, erectile dysfunction, respiratory diseases, allergy, ophthalmic diseases, containing one or more of the following active ingredients - cromolin sodium, amlodipin besylate, alendronate sodium, chlorazepate dipotassium, atropine sulphate, atorvastatin calcium, candesartan cilexetil, ceftriaxone sodium, ephedrine hcl, guaiphenesine, zafirlukast, donepezil hcl, diflunisal, dipyridamole, famotidine, losartan potassium, hydro-chlorothiazide, meloxicam, phenyleprine hcl, fexofenadine hcl, indapamide, sulfisoxazole, clopidogrel, lansoprazole, clarithromycin, flurbiprofen, nimesulide, pantoprazole, paracetamole, pilocarpine hcl, lisinopril, pseudoephedrine hcl, ciprofloxacin hcl, sertraline hcl, cyclopentolate hcl, dihydroergotoxine methansulfonate, terbinafine, timolol maleate, tiamphenicol, azithromycin, tenoxicam, fluconazole, digoxine, tioconazole, dimenhydrinate, quinidine arabogalactane sulphate, quinidine phenylethyl barbiturate, diltiazem hcl, buspirone hcl, amiodarone hcl, trazodone, difluprednate, enoxacin, lactulose, ketorolac, pentoxifylline, vitamin e, chlorhexidine, cetrimide, propyphenazone, caffeine, cetirizine, phenylpropanolamine, zolpidem, bacampicillin hcl, roxithromycin, sultamicillin tosilate, acetylsalicylic acid, ampicillin na, sulbactam na, sildenafil citrate, ambroxol hcl, ribavirin, loratadine, etodolac, omeprazole, oxybutynin chloride, quinidine sulphate, olanzapine, raloxifen, pioglitazone, moxifloxacin, rosiglitazone, sibutramin, carvedilol, montelukast, citalopram, gliclazide, cefaclor, ezetimibe, rofecoxib, quetiapine fumarate, metformin hcl, acarbose, chlorpheniramine maleate, nateglinide, leflunomide, valsartan, cefazolin sodium, diacerein, paroxetine, levofloxacin, levetiracetam, zolmitriptan, glibenclamide, tizanidine, perindopril erbumine, ramipril, ceftazidime, cefuroxime axetyl, thiocolchicoside, acamprosate, acetylcysteine, alpha calcidol, alpha lipoic acid, aripiprazole, atomoxetine, balsalazide disodium, butenafine hcl, calcitriol, carbonyl iron, folic acid, calcium carbonate, magnesium hydroxide, cefdinir, cefepime hcl, cefixime, cefpodoxime proxetil, cefprozil, cephalexine monohydrate, ciclesonide, cilazapril, cilostazol, cinitapride, citicoline, co-enzyme q10, darifenasin, deferiprone, dothiepin, duloxetine, eletriptan, escitalopram, esomeprazole, etoricoxib, felodipine, fenofibrate, ferrous sulphate, zinc sulphate, fluvastatin, frovatriptan, gabapentin, galantamine, gemifloxacin, ginkgo biloba, glimepride, granisetron, ibandronate, irbesartan, iron hydroxide polymaltose, lamivudine, lamotrigine, levetiracetam, letrozole, linezolide, memantine hcl, metoprolol, midodrine, mirtazapine, mizolastine, mosapride citrate dihydrate, mycophenolate mofetil, nebivolol, nefazodone, niacin, nitazoxanide, ondansetron, ornidazole, oxcarbazepine, pimecrolimus, pravastatin, pregabalin, rabeprazol, rebamipide, repaglinide, risedronate, risperidone, rivastigmine, rosuvastatin, saccharomyces boulardii, tacrolimus, tadalafil, tamsulosin hcl, tazaroten, tazobactam sodium, piperacillin sodium, tegaserod, telithromycin, terazocin, teriparatide, tolterodine tartrate, topiramate, trandolapril, trimethazidine, valacyclovir, valproate sodium, venlafaxine, voriconazole, ximelagatran, zaleplon, ziprasidone, zoledronic acid | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ARVEN ILAÇ SANAYI VE TICARET ANONIM SIRKETI
- Other trademarks owned by ARVEN ILAÇ SANAYI VE TICARET ANONIM SIRKETI
- Other trademarks owned by ARVEN ILAÇ SANAYI VE TICARET ANONIM SIRKETI
- Other trademarks in Class 005
- Similar marks named ARVEN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 25, 2025 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Apr 25, 2025 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Feb 5, 2024 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Jan 17, 2024 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Jan 17, 2024 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Jan 5, 2024 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| May 5, 2023 | C71T | CANCELLED SECTION 71 | — |
| Oct 18, 2021 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| May 7, 2020 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 25, 2018 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 14, 2017 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 23, 2017 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Feb 23, 2017 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Jan 18, 2017 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 18, 2016 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Oct 18, 2016 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 12, 2016 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 12, 2016 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Aug 12, 2016 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Aug 2, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 2, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 13, 2016 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 13, 2016 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jul 13, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 29, 2016 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jun 23, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 23, 2016 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 23, 2016 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 23, 2016 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 23, 2016 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 5, 2016 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jan 5, 2016 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 5, 2016 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 15, 2015 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 15, 2015 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 10, 2015 | ALIE | ASSIGNED TO LIE | — |
| Nov 30, 2015 | ALIE | ASSIGNED TO LIE | — |
| Nov 12, 2015 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 2, 2015 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 1, 2015 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 1, 2015 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 15, 2015 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 13, 2015 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 13, 2015 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 13, 2015 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 12, 2015 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 11, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| May 11, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 7, 2015 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |